Clinical trials: Depression / Major Depressive Disorder
Depression
Fevarin® Effectiveness in Treatment of Depression in Patients With Neurological Disorder
Prospective, multicenter, non-comparative, observational program to describe prevalence of depressive symptoms in a variety of neurological disorders and effects of Fevarin® on the severity of anxiety and depression, sleep state…
- Trial name
- FRIENDS (NCT02043197)
- Where
- 29 sites in Russia
- Volunteers
- 300 people
- Sponsor
- Abbott
Major Depressive Disorder
A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD)
This is an outpatient, 2-arm, Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of REL-1017 once daily (QD) as a monotherapy for Major Depressive Disorder.
- Trial name
- Reliance III (NCT05081167)
- Testing
- REL-1017
- Where
- 10 sites in United States
- Volunteers
- 232 people
- Sponsor
- Relmada Therapeutics, Inc.
Major Depressive Disorder
Comparison of Behavioral Activation and Antidepressant Medication in the Treatment of Adolescents With Depression
This study focuses on treating adolescents with depression. The study has two main purposes. The first is to compare a new form of therapy for depression called Behavioral Activation (BA) to the antidepressant medication…
- Trial name
- NCT01740726
- Testing
- Behavioral Activation, Fluoxetine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Emory University
Depression
Role of Slow-wave Activity and Plasticity in MDD
The hypothesis underlying this proposal is that deficits of synaptic plasticity underlie the slow-wave activity (SWA) abnormalities observed n major depressive disorder (MDD), and that manipulating SWA may serve to circumvent…
- Trial name
- SWIP (NCT04150718)
- Testing
- slow-wave disruption
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Depression, Major Depressive Disorder
Nitrous Oxide as Treatment for Major Depression - a Pilot Study
Major depressive disorder (MDD) is a global medical problem with significant shortcomings in current therapy. Chief among these is the delay between initiation of pharmacologic therapy and clinical improvement in symptoms.
- Trial name
- NCT02139540
- Testing
- Nitrous Oxide
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Washington University School of Medicine
Depression
Pre-Treatment Positron Emission Topography Scanning for Increasing Success in Antidepressant Treatment
This study will use pre-treatment positron emission topography and functional magnetic resonance imaging scans of the brain to predict the most effective antidepressant treatment for people with major depressive disorder.
- Trial name
- NCT00456014
- Testing
- Escitalopram, Desipramine
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- New York State Psychiatric Institute
Smoking Cessation, Cigarette Smoking
Treating Smokers With Mental Illness
This is a smoking cessation study that will enroll smokers who have been diagnosed with a severe mental illness. The study will use a combination of intensive tobacco treatment counseling and nicotine replacement therapy to…
- Conditions
- Smoking Cessation, Cigarette Smoking, Schizophrenia, Psychotic Disorders
- Trial name
- NCT03822416
- Testing
- Nicotine patch, Nicotine lozenge, Therapy
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Major Depressive Disorder
Mechanisms of Antidepressant Non-Response in Late-Life Depression
This project seeks to elucidate the mechanisms by which antidepressant medications have limited efficacy in Late Life Depression (LLD) in order to develop new treatment interventions for this prevalent and disabling illness.
- Trial name
- NCT01931202
- Testing
- Escitalopram
- Where
- United States
- Volunteers
- 138 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder, Cognitive Behavior Therapy
Using a Text-message System to Engage Depressed Adolescents in Cognitive-behavioral Therapy Homework
The primary goal of the pilot is to test the feasibility and utility of using a text-messaging system to engage adolescents in improved homework adherence during cognitive-behavioral therapy (CBT) for major depressive disorder.
- Conditions
- Major Depressive Disorder, Cognitive Behavior Therapy, Text Messaging
- Trial name
- NCT00919932
- Testing
- Paper and pen homework, Text message system homework.
- Volunteers
- 9 people
- Sponsor
- University of Pittsburgh
Major Depressive Disorder
A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder
The purpose of this study is to assess the effect and safety of AZD6765 in patients with major depressive disorder who exhibit inadequate response to antidepressants.
- Trial name
- NCT01482221
- Testing
- AZD6765 iv
- Where
- 44 sites in United States, Chile and 2 more
- Volunteers
- 542 people
- Sponsor
- AstraZeneca
Schizophrenia, Bipolar Disorder
Multi-modal Assessment of Gamma-aminobutyric Acid (GABA) Function in Psychosis
The purpose of this study is to better understand mental illness and will test the hypotheses that, while viewing affective stimuli, patient groups will show increased blood oxygenation level dependent (BOLD) signal by fMRI after…
- Conditions
- Schizophrenia, Bipolar Disorder, Healthy, Psychosis
- Trial name
- GABAmech (NCT04004416)
- Testing
- Lorazepam and fMRI
- Where
- United States
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Major Depressive Disorder, Depression
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder
The purpose of this study is to determine if TC-5214 or placebo (a tablet that looks like medicine tablet or capsule, but contains no active medicine) is safe and effective when taken together with another antidepressant.
- Trial name
- NCT01180400
- Testing
- TC-5214
- Where
- 66 sites in Czechia, Estonia and 8 more
- Volunteers
- 295 people
- Sponsor
- AstraZeneca
Major Depressive Disorder
Supportive and Supportive-Expressive Treatment for Depression
This study will assign patients to two types of psychotherapies in treating people with a major depression disorder, expressive versus supportive techniques, and will examine their ability to benefit from treatment based on their…
- Trial name
- SSETD (NCT02728557)
- Testing
- Supportive-Expressive Therapy, Supportive Therapy
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- University of Haifa
Major Depressive Disorder
A Study of LY2216684 in Healthy Participants Receiving Albuterol or Propanolol
The purpose of this study is to determine the effect of LY2216684 on heart rate of participants receiving Albuterol and Propranolol. Information about any side effects that may occur will also be collected.
- Trial name
- NCT01263197
- Testing
- LY2216684, albuterol, propranolol
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Depressive Disorder, Major
A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy
The purpose of this study is to assess the efficacy of flexibly dosed JNJ-42847922 (20 milligram [mg] or 40 mg) compared to flexibly dosed quetiapine extended-release (XR) (150 mg or 300 mg) as adjunctive therapy to an…
- Trial name
- NCT03321526
- Testing
- JNJ-42847922, Quetiapine XR, Selective Serotonin Reuptake Inhibitor (SSRI)
- Where
- 50 sites in United States
- Volunteers
- 107 people
- Sponsor
- Janssen Research & Development, LLC
Depressive Disorder, Major
Paroxetine-referenced Study Evaluating Three Doses of DVS SR in Outpatients With MDD
This study will assess the safety, tolerability and efficacy of desvenlafaxine succinate sustained release (DVS SR) in subjects with major depressive disorder.
- Trial name
- NCT00445679
- Testing
- DVS SR, Paroxetine
- Where
- 43 sites in China, India and 2 more
- Volunteers
- 807 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Schizophrenia, Schizoaffective Disorder
The Effectiveness of FMPO in Improving the Quality of Care for Persons With Severe Mental Illness.
The purpose of this study is to learn how to help veterans play a stronger role in shaping their mental health care. Specifically we want to see if we can help veterans improve their mental health treatment by helping them decide…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Major Depression
- Trial name
- NCT00466323
- Testing
- Family Member Provider Outreach, Enhanced treatment as usual (e-TAU)
- Where
- 2 sites in United States
- Volunteers
- 238 people
- Sponsor
- US Department of Veterans Affairs
Major Depressive Disorder
Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy in Patients With Major Depressive Disorder
The objective of this study is to evaluate the long-term safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with Major Depressive Disorder (MDD).
- Trial name
- NCT01838876
- Testing
- Cariprazine, Antidepressant Therapy (ADT)
- Where
- 90 sites in United States, Puerto Rico
- Volunteers
- 442 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder With Psychotic Features
Study of Pharmacotherapy of Psychotic Depression
This study will determine the effectiveness of combining selective serotonin reuptake inhibitors (SSRIs) with antipsychotic medications in the treatment of psychotic depression.
- Trial name
- STOP-PD (NCT00056472)
- Testing
- Olanzapine, Sertraline
- Where
- 4 sites in United States, Canada
- Volunteers
- 259 people
- Sponsor
- Weill Medical College of Cornell University
Prodromal Schizophrenia, Psychotic Disorders
Psychosis: Early Detection, Intervention and Prevention
The primary aim of this application is to conduct a randomized, controlled clinical trial of a specialized mental health service delivery system specifically developed for prodromal psychotic disorders.
- Conditions
- Prodromal Schizophrenia, Psychotic Disorders, Severe Bipolar Disorder With Psychotic Features, Severe Major Depression With Psychotic Features
- Trial name
- EDIP (NCT01597141)
- Testing
- Family-aided Assertive Community Treatment, Enhanced standard treatment
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- MaineHealth